for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Yifan Pharmaceutical Co Ltd

002019.SZ

Latest Trade

15.82CNY

Change

-0.22(-1.37%)

Volume

7,702,274

Today's Range

15.66

 - 

16.23

52 Week Range

13.03

 - 

26.64

As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
16.04
Open
15.91
Volume
7,702,274
3M AVG Volume
221.28
Today's High
16.23
Today's Low
15.66
52 Week High
26.64
52 Week Low
13.03
Shares Out (MIL)
1,208.61
Market Cap (MIL)
19,795.06
Forward P/E
29.43
Dividend (Yield %)
0.31

Next Event

Q3 2021 Yifan Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Yifan Pharmaceutical Says 6-Month Net Profit Down 70.3% Y/Y

Yifan Pharmaceutical Sees 6-Month Net Profit Down 65-75% Y/Y

Yifan Pharmaceutical's 2020 Net Profit Up 7.2% Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Yifan Pharmaceutical Co Ltd

YIFAN XINFU PHARMACEUTICAL CO.,LTD, is a China-based company primarily engaged in production and sale of polymer materials. The Company operates in three segments, including Pharmaceuticals, Pharmaceutical Raw Material and Intermediates, as well as Polymer Materials. The Company's main products include D-calcium pantothenate, D- panthenol, poly butylenes succinate and others. The Company distributes its products in domestic and overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No. 50

Qinshan, Jincheng Street, LinAn City

HANGZHOU, ZHJ

311300

China

+86.551.62672019

https://www.yifanyy.com/

Executive Leadership

Xianfeng Cheng

Chairman of the Board, General Manager

Haixia Yu

Chief Financial Officer

Hang Lin

Deputy General Manager, Director

Benyu Zhou

Chief Audit, Director

Deqi Feng

Secretary of the Board, Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

4.6K

2019

5.2K

2020

5.4K

2021(E)

5.1K
EPS (CNY)

2018

0.610

2019

0.740

2020

0.790

2021(E)

0.545
Price To Earnings (TTM)
42.07
Price To Sales (TTM)
3.99
Price To Book (MRQ)
2.25
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
23.39
LT Debt To Equity (MRQ)
7.26
Return on Investment (TTM)
4.45
Return on Equity (TTM)
3.45

Latest News

Latest News

BRIEF-Yifan Pharmaceutical Plans To Issue Debt Financing Instruments Worth Up To 300 Mln Yuan

* SAYS IT PLANS TO ISSUE DEBT FINANCING INSTRUMENTS WORTH UP TO 300 MILLION YUAN ($43.70 million) Source text in Chinese: https://bit.ly/2QE5Vvi Further company coverage: ($1 = 6.8647 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Yifan Pharmaceutical's Q1 Net Profit Up 119.8% Y/Y

* SAYS Q1 NET PROFIT UP 119.8% Y/Y AT 323.4 MILLION YUAN ($45.70 million) Source text in Chinese: https://reurl.cc/0o9V46 Further company coverage: ($1 = 7.0773 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Yifan Pharmaceutical's 2019 Net Profit Up 22.5% Y/Y

* SAYS 2019 NET PROFIT UP 22.5% Y/Y AT 903.5 MILLION YUAN ($128.20 million)

BRIEF-Yifan Pharmaceutical's Prelim 2019 Net Profit Up 23.5% Y/Y

* SAYS ITS PRELIM 2019 NET PROFIT UP 23.5% Y/Y AT 911.0 MILLION YUAN ($129.91 million) Source text in Chinese: shorturl.at/muyBV Further company coverage: ($1 = 7.0128 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up